CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) Comprehensive intravascular ultrasound assessment of stent area and its impact on restenosis and adverse cardiac events in 403 patients with unprotected left main disease Cardiovascular Magnetic Resonance as a complementary method to Transthoracic Echocardiography for Aortic Valve Area Estimation in patients with Aortic Stenosis: A systematic review and meta-analysis Echocardiographic Screening for Pulmonary Hypertension in Congenital Heart Disease: JACC Review Topic of the Week Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Why NOBLE and EXCEL Are Consistent With Each Other and With Previous Trials Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement Active SB-P Versus Conventional Approach to the Protection of High-Risk Side Branches: The CIT-RESOLVE Trial The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study Primary Prevention Trial Designs Using Coronary Imaging: A National Heart, Lung, and Blood Institute Workshop

Original Research2021 Jan 10;S1547-5271(21)00009-6.

JOURNAL:Heart Rhythm. Article Link

Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia Burden

S Tankut, I Goldenberg, V Kutyifa et al. Keywords: cardiac resynchronization therapy; heart failure; left bundle branch block; ventricular fibrillation; ventricular tachycardia arrhythmia.

ABSTRACT


BACKGROUND - Cardiac resynchronization therapy-defibrillator (CRT-D) may reduce the incidence of first ventricular tachyarrhythmia (VTA) in patients with heart failure (HF) and left bundle-branch-block (LBBB).

 

OBJECTIVE - To assess the effect of CRT-D on VTA burden in LBBB patients.

 

METHODS - We included 1281 patients with LBBB from MADIT-CRT. VTA was defined as any treated or monitored sustained ventricular tachycardia (VT180 bpm) or ventricular fibrillation (VF). Life-threatening VTA was defined as VT200 bpm or VF. VTA recurrence was assessed using the Andersen-Gill model.

 

RESULTS - During a mean follow-up of 2.5 years, 964 VTA episodes occurred in 264 (21%) patients. The VTA rate per 100 person-years was significantly lower in the CRT-D group when compared with the ICD group (20 vs. 34; respectively; p<0.01). Multivariate analysis demonstrated that CRT-D treatment was associated with a 32% risk reduction for VTA recurrence (HR=0.68; 95%CI 0.57-0.82; p<0.001), 57% risk reduction for recurrent life-threatening VTA, 54% risk reduction for recurrent appropriate ICD-shocks, and a 25% risk reduction for the combined endpoint of VTA and death. The effect of CRT on VTA burden was consistent among all tested subgroups, but was more pronounced among NYHA class I patients. Landmark analysis showed that at 2 years, the cumulative probability of death subsequent to year one was highest (16%) among patients who had 2 VTA events during their first year.

 

CONCLUSION - In patients with LBBB and HF, early intervention with CRT-D reduces mortality, VTA burden, and frequency of multiple appropriate ICD shocks. VTA burden is a powerful predictor of subsequent mortality.